Literature DB >> 21550659

Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.

Norina Tanaka1, Yan-Hua Wang, Masayuki Shiseki, Minoko Takanashi, Toshiko Motoji.   

Abstract

The preferentially expressed antigen of melanoma (PRAME) is known as a tumor-associated antigen, but its function in leukemia remains unclear. We investigated the function with small interfering RNA (siRNA)-induced knockdown of PRAME in a K562 cell line. After PRAME siRNA transfection, proliferation was suppressed and cell cycle analysis showed G(0)/G(1) arrest, followed by apoptosis. PRAME siRNA-treated cells also showed changes in the genes affecting erythroid differentiation. We examined the PRAME expression levels and the S phase population of 32 acute leukemia patients at the time of diagnosis and relapse. An increase of the S phase population was accompanied by an increase of PRAME expression at relapse. Our results suggest that PRAME plays an important role in disease progression in acute leukemia.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550659     DOI: 10.1016/j.leukres.2011.04.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?

Authors:  Miroslaw J Szczepanski; Theresa L Whiteside
Journal:  Biomark Med       Date:  2013-08       Impact factor: 2.851

2.  Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Ya-Zhen Qin; Yan-Huan Zhang; Xiao-Ying Qin; Hong-Hu Zhu
Journal:  Oncol Lett       Date:  2017-02-28       Impact factor: 2.967

3.  [Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the PRAME gene].

Authors:  Feng Zhang; Ai-Dong Lu; Ying-Xi Zuo; Ming-Ming Ding; Yue-Ping Jia; Le-Ping Zhang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-05-15

4.  Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy.

Authors:  Kenjiro Mitsuhashi; Akihiro Masuda; Yan-Hua Wang; Masayuki Shiseki; Toshiko Motoji
Journal:  Int J Hematol       Date:  2014-05-13       Impact factor: 2.490

5.  PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.

Authors:  Yu Xu; Qingcai Yue; Hong Wei; Guiju Pan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

6.  Genome-wide promoter methylation profile of human testis and epididymis: identified from cell-free seminal DNA.

Authors:  Chunlin Wu; Xiaofang Ding; Honggang Li; Changhong Zhu; Chengliang Xiong
Journal:  BMC Genomics       Date:  2013-04-28       Impact factor: 3.969

7.  Identification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma.

Authors:  Quan Huang; Lin Li; Zaijun Lin; Wei Xu; Shuai Han; Chenglong Zhao; Lei Li; Wenjiao Cao; Xinghai Yang; Haifeng Wei; Jianru Xiao
Journal:  Med Sci Monit       Date:  2016-05-31

Review 8.  The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.

Authors:  Yichi Xu; Ruanmin Zou; Jing Wang; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Cell Prolif       Date:  2020-02-05       Impact factor: 6.831

9.  The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME.

Authors:  Adalberto Costessi; Nawel Mahrour; Vikram Sharma; Rieka Stunnenberg; Marieke A Stoel; Esther Tijchon; Joan W Conaway; Ronald C Conaway; Hendrik G Stunnenberg
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

10.  PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.

Authors:  Ghaneya Al-Khadairi; Adviti Naik; Remy Thomas; Boshra Al-Sulaiti; Shaheen Rizly; Julie Decock
Journal:  J Transl Med       Date:  2019-01-03       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.